Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dyadic InternationalDYAI -2.02%38 Days Sales Outstanding is 301.35 as of Jun. 2026, which is 419% above its 10-year median of 58.11. GuruFocus rates DYAI with a GF Score™ of 38/100 and a GF Value™ of $0.58 (Fairly Valued). The stock has 7 warning signs investors should review. Among 841 Biotechnology companies, Dyadic International ranks worse than 74.44% on this metric.
Dyadic International (NAS:DYAI) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Dyadic International Days Sales Outstanding Related Terms
Dyadic International Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Dyadic International's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DYAI vs PVCT, TVRD, ATOS: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Dyadic International's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dyadic International Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dyadic International's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Dyadic International's Days Sales Outstanding falls into.
Dyadic International Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 301.35 mean?
Dyadic International (DYAI) has a Days Sales Outstanding of 301.35 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Dyadic International and its competitors. This is 419% above median its historical median of 58.11. Over the past decade, Dyadic International's Days Sales Outstanding has ranged from 13.45 to 107.97. According to the industry distribution chart, Dyadic International ranks #626 out of 841 companies in the Biotechnology industry, placing it in the top 74.4%.
Is Dyadic International's Days Sales Outstanding too high?
Dyadic International's current Days Sales Outstanding of 301.35 is 419% above median its 10-year median of 58.11. Over the past 10 years, this metric has ranged from a low of 13.45 to a high of 107.97. The Biotechnology industry median Days Sales Outstanding is 68.98. Dyadic International's value of 301.35 is 336.9% above this industry median. Based on the distribution chart, Dyadic International ranks #626 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Dyadic International has a GF Score™ of 38/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dyadic International's Days Sales Outstanding compare to PVCT and TVRD?
According to the Biotechnology industry distribution chart, Dyadic International ranks #626 out of 841 companies for Days Sales Outstanding. This places Dyadic International in the lower half of its industry. The industry median Days Sales Outstanding is 68.98. Dyadic International's value of 301.35 is 336.9% above this benchmark. Historically, Dyadic International's own Days Sales Outstanding has ranged from 13.45 to 107.97 over the past decade. While the company's 10-year median is 58.11 vs. the industry median of 68.98, Dyadic International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dyadic International's current Days Sales Outstanding of 301.35 is 336.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Dyadic International and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dyadic International's current Days Sales Outstanding is 301.35, which is 419% above median its own 10-year median of 58.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dyadic International stock overvalued right now?
Based on GuruFocus' analysis, Dyadic International (DYAI) is currently considered Fairly Valued. The stock's GF Value™ is $0.58, compared to a current price of $0.52 — trading 9.6% below its estimated fair value. The current Days Sales Outstanding is 301.35, which is 419% above median its 10-year median of 58.11 and 336.9% above the Biotechnology industry median of 68.98. Dyadic International's overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Dyadic International (DYAI), the current Days Sales Outstanding is 301.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dyadic International (DYAI) Overvalued in 2026?
Based on GuruFocus' analysis, Dyadic International stock appears to be undervalued.
The current stock price of $0.52 is trading 9.6% below its estimated GF Value™ of $0.58.
GuruFocus considers Dyadic International to be Fairly Valued.
Key valuation signals for DYAI:
Days Sales Outstanding: 301.35 (419% above median its 10-year median of 58.11)
GF Value™: $0.58 vs. price of $0.52 (9.6% below fair value)
Industry Position: 336.9% above the Biotechnology median (#626 of 841)
No single metric tells the full story. See the DYAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
38GF Score
Get the complete analysis for DYAI
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYAI has been successfully added to your 
